When a controlled in-vitro protocol lists more than one peptide sequence, purchasing teams often ask whether they can order a single combined vial. The supplier’s statement “no blended peptides” is not a comment on the scientific rationale for studying two sequences; it defines what is supplied and what must be documented. For a laboratory preparing for an external quality-system inspection, that distinction shapes sample identity, batch records, storage and chain of custody. All materials discussed are research-use-only and are not for human or veterinary use. They are not medicines, medical devices, injectables, treatments or food supplements, and they should not be used for therapeutic, clinical or diagnostic purposes.
What “No Blended Peptides” Means in a Research Supply Context
No blended peptides means the supplier does not offer a pre-mixed vial containing two or more sequences. Research Sciences’ FAQs state that it does not supply blended peptides — for example, Ipamorelin + CJC-1295 — and recommends buying peptides individually and combining only within a controlled experimental design. The catalogue therefore treats each sequence as a separate line item, with its own label reference and its own CoA. If a protocol lists BPC-157 and TB-500, procurement should expect two vials, two batch records and two analytical documents, not one combined vial. This is the point an external assessor will test: whether the materials received match the protocol’s components and whether each component can be traced independently.
For a supplier such as Research Sciences — which lists research-use-only Uk peptides alongside laboratory accessories — the statement is part of the RUO position, not a formulation instruction. It does not mean the laboratory cannot study two sequences in one experimental design. It means the combination step, if required, belongs to the controlled laboratory workflow and must be documented there. The shop’s published page should be reconfirmed at the time of ordering, and the batch CoA should be opened and checked for the specific lot supplied.
Why a single blended CoA is weaker evidence
External quality-system inspections look for clarity: a single certificate covering a mixture may not show whether the stated purity applies to each sequence, whether identity was confirmed for both components, or whether contaminant screening was performed on the combined material. Individual vials allow each sequence to be linked to its own SKU-and-expiry label reference, such as BPC10-03/27, and to the corresponding CoA. The shop describes its CoAs as batch-level documents; researchers should verify the actual batch document rather than relying on a homepage summary. Internal Test References may link to associated sample testing reports, but the FAQs note that an ITR does not confirm that separate deliveries come from the same production lot or have had separate independent testing. That distinction matters when an assessor asks for traceability across two sequences.
Preparing the Audit Trail When a Protocol Lists More Than One Sequence
Ahead of an external quality-system inspection, the practical question is not whether the protocol can list two sequences; it is whether the laboratory can evidence what happened to each sequence. Create a materials receipt record for each vial: supplier, catalogue item, label reference, expiry, CoA identifier, date received, storage location and any visible condition. Store lyophilised materials at −20°C or below, sealed with desiccant and protected from moisture, heat and light, in line with the shop’s handling guidance. Avoid repeated freeze–thaw cycles. If a vial is reconstituted for an in-vitro assay, record the diluent volume, concentration, date, analyst and short-term 2–8°C laboratory storage. Keep this inside the laboratory workflow; the shop’s calculator and materials are not for medical or clinical use.
The combination record belongs in the laboratory, not the catalogue
If the protocol requires both sequences in one assay system, write a combination record that names the two separate vials, their CoAs and the exact volumes used to prepare the working concentration. Do not rely on a supplier to provide a blended product. The shop’s statement that it does not supply blended peptides means the combination is an experimental step; the record should show who prepared it, when, with which diluent, and how unused material was stored or disposed of. Cap colour should not be used as an identity check; the FAQs state that cap colours and other packaging may vary and are not indicators of identity, analytical quality or manufacturing origin. Where a restocked item carries the same ITR as earlier stock, treat the ITR as a link to associated sample testing reports, not as proof of a single production lot. Use label references and CoAs, not packaging appearance, as the audit thread.
Materials managers should also keep the supplier’s RUO statement and the batch CoA together with the receiving record. This makes clear that the materials were supplied for controlled laboratory and analytical research only, and that the purchaser remains responsible for lawful use, safe handling, storage, disposal and compliance with relevant UK regulations, including COSHH and laboratory safety standards. An inspection pack should show the protocol’s sequence list on one side and the corresponding label references and CoAs on the other. If a sequence was not used, record that too; an assessor may ask why it was ordered, how it was stored and whether it remained within its labelled expiry.
What External Reviewers Usually Ask — and How to Answer with Individual Vials
An external quality-system assessor may begin with the protocol and ask for a component map. For each sequence, supply the catalogue item, label reference and batch CoA. If the protocol lists two sequences but the order was placed as two individual items, show the two order lines and two receipt records. If someone in the laboratory prepared a combined working solution, show the in-vitro preparation record. If no combination was prepared, state that the sequences were studied separately or in parallel. The no blended peptides policy makes this mapping cleaner because each sequence has its own documentary identity, its own storage entry and its own analytical reference.
Supplier qualification and published claims
Supplier qualification should include the live catalogue page, the RUO statement and the batch CoA. Research Sciences publishes RUO compliance language, testing references and CoA access; its homepage lists “CoAs Janoshik Analytical Reports” and purity statements such as “≥99% Verified Purity”. These are shop-published claims and should be reconfirmed against the live page and the specific batch CoA before an inspection. Do not substitute a homepage headline for the batch document. The FAQs describe full-spectrum testing as purity, identity, heavy metals and endotoxin evaluation of submitted samples; researchers should verify the actual certificate rather than assume the same testing applies to every lot.
A useful real-world scenario: a laboratory protocol lists Ipamorelin and CJC-1295 (No DAC). The purchasing team orders each as a separate 5mg item. On receipt, the materials manager logs two label references and two CoAs. The researcher prepares separate stock solutions in an in-vitro workflow and records the volumes used in the assay. At inspection, the assessor can follow each sequence from order to vial to CoA to preparation record. If the laboratory had instead assumed a blended vial, the audit trail would risk a gap at the very point an assessor tests: whether the material in the assay can be traced to the sequence named in the protocol. The same logic applies to other catalogue items; confirm item details on the live site and the batch CoA. All materials remain research-use-only and are not for human or veterinary use.
Casablanca chemist turned Montréal kombucha brewer. Khadija writes on fermentation science, Quebec winter cycling, and Moroccan Andalusian music history. She ages batches in reclaimed maple barrels and blogs tasting notes like wine poetry.